SARASOTA, FLORIDA / ACCESS Newswire / January 20, 2026 / Specificity (OTCID:SPTY), a leading hybrid AdTech company specializing in bot-free, intent-based digital marketing solutions, today announced a series of milestones that underscore its robust financial health and positioning for accelerated growth in the coming year. These developments highlight the company’s commitment to delivering superior value to clients and shareholders alike, amid a rapidly evolving digital advertising landscape plagued by fraud and inefficiency.

In November 2025, Specificity achieved positive operating cash flow ahead of expectations, driven by a surge in new client acquisitions during the fourth quarter. This marks a pivotal shift toward sustainable profitability, with the company adding over $400,000 in annual run-rate revenue in December 2025 alone. "Our focus on human-verified, bot-free targeting is resonating with brands seeking real results," said Jason Wood, CEO of Specificity "By eliminating waste from fraudulent traffic, we’re not only boosting client ROI but also building a resilient business model that positions us for long-term success."

A standout achievement includes the company’s wildly successful inaugural month partnering with the third-largest travel website in Europe, which generates over $75 million annually. Leveraging Specificity’s proprietary AI-powered ad verification and intent data technologies, the campaign delivered an impressive 38X internal rate of return (IRR) through precise, fraud-free targeting. This collaboration exemplifies Specificity’s ability to drive measurable outcomes across industries, from travel and e-commerce to solar energy and retail, and many more, where clients have reported traffic increases of up to 217%, lead generation surges, and revenue growth in the hundreds of thousands.

Further bolstering its growth trajectory, Specificity recently signed a Letter of Intent (LOI) with Blackpearl Group to develop the world’s only fully integrated AdTech stack. This partnership aims to launch a direct challenge to Big Tech’s fraud-ridden ecosystems, combining Specificity’s audience resolution tools with advanced CRM integrations and first-party data building. Additionally, the company’s effective S-1 registration statement paves the way for access to expansion capital, enabling investments in proprietary technologies like Polygon for hyper-granular targeting and AI-driven analytics.

Financially, Specificity reported revenue of $260,000 for the quarter ending September 30, 2025, reflecting 21.7% growth quarter-over-quarter. Operating expenses declined 37.9% year-over-year to $162,754, demonstrating disciplined cost management. We are already hard at work putting together the 4Q numbers and look forward to releasing those results shortly. With billions of impressions served, many millions of website visits driven, and hundreds of millions in client revenue generated to date, Specificity continues to lead in creating clean, compliant data assets that empower brands in a post-cookie world.

"2025 was a breakthrough year, and 2026 will be one of serious expansion," added Wood. "Our hybrid model-blending creative agency expertise with cutting-edge AdTech-has proven its edge in combating the $84 billion annual fraud in digital advertising. We’re platform-agnostic, focusing on Connected TV (CTV), social, display, and automated workflows to reach high-intent audiences where they are. Investors can expect continued momentum as we capitalize on market shifts toward transparency and efficiency."

Specificity’s innovations have attracted the market’s attention and testimonials from long-term clients and new clients from both small business and enterprise level brands that can be seen on their website. As streaming surpasses traditional TV-with 85% of U.S. households subscribed to platforms and ad views up 45% since 2020-Specificity finds itself perfectly positioned to capture massive market share in this booming sector and has already developed technology to serve connected TV ads to high intent audiences.

For more information, visit www.specificityinc.com or contact investor relations at ir@specificityinc.com.

About Specificity

Specificity (OTCID:SPTY) is a Tampa-based digital marketing firm revolutionizing the industry through bot-free, intent-driven data and targeted advertising. By integrating agency services with advanced AdTech, Specificity helps brands eliminate fraud, build first-party audiences, and achieve superior ROI across channels. With billions of data points and impressions served, the company delivers results for clients nationwide.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Specificity undertakes no obligation to update these statements except as required by law.

SOURCE: Specificity Inc.

View the original press release on ACCESS Newswire

ATLANTIC CITY, NJ AND VANCOUVER, BC / ACCESS Newswire / January 20, 2026 / FendX Technologies Inc.(CSE:FNDX)(OTCQB:FDXTF)(FSE:E8D) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

Carolyn Myers, CEO of FendX, will deliver a company presentation and be available for one-on-one investor meetings throughout the event to discuss the Company’s recent developments, growth strategy and investment opportunities.

Event Details:

• 3rd Annual DealFlow Discovery Conference

• The Borgata Hotel, Casino & Spa

• Atlantic City, NJ

• January 28-29, 2026

Investors interested in scheduling a meeting with the FendX management team should request an investor pass to attend the conference (no cost to attend).

About FendX Technologies Inc.

FendX is a surface protection company developing innovative solutions to help reduce the spread of harmful pathogens in everyday environments. Leveraging proprietary technologies, The Company is advancing a portfolio of protective surface coatings, including REPELWRAP™ film, a liquid-based nano- coating technology and a specialized Foley catheter coating. The Company is focused on building a robust intellectual property portfolio in the surface protection space and is committed to identifying and advancing new technologies and materials that enhance hygiene and safety across healthcare, consumer and commercial settings.

Media Contact:

Carolyn Myers
1-800-344-9868
investor@fendxtech.com

For more information, please visit https://fendxtech.com/ and the Company’s profile on SEDAR+ at www.sedarplus.ca.

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate, and that actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company’s public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company’s such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors should change.

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will participate in the DealFlow Discovery Conference, taking place January 28th and 29th, 2026.

Anil R. Diwan, PhD, President and Executive Chairman of the Company will deliver a company presentation on Thursday, January 29th at 11:00 am ET, and will be available for one-on-one investor meetings throughout the event.

NanoViricides is developing first-in-class antiviral drugs that act by a novel mechanism of action, enabling unparalleled broad-spectrum antiviral activity as well as safety. The Nanoviricides technology defines a novel antiviral mode of action that we call "Re-Infection Inhibition". A "nanoviricide™" is designed to look like a cell to the virus, presenting a high concentration of virus-binding ligands on its surface. Upon binding of the virus, the nanoviricide is further designed to change shape and engulf the virus particle, rendering it incapable of infecting cells.

Event Details:

• Conference: 3rd Annual DealFlow Discovery Conference

• Venue: The Borgata Hotel, Casino & Spa

• Location: Atlantic City, NJ

• Date: January 28th-29th, 2026

Investors interested in scheduling a meeting with the NanoViricides management team should request an investor pass to attend the conference by registering (no cost to attend) at the Conference website (https://dealflowdiscoveryconference.com/investors/ ).

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. NV-387 is a unique broad-spectrum antiviral that is also effective in animal models for Monkeypox (MPox), Smallpox, as well as Measles.

Our other advanced drug candidate is NV-HHV-1 for the treatment of all Herpesvirus infections including HSV-1 "cold sores", HSV-2 "genital ulcers, VZV Shingles and Chickenpox. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants.

NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

Forward-looking statements: This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Media Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: DealFlow Events

View the original press release on ACCESS Newswire

• Collaboration enables integrated device-plus-AI offerings supporting scalable ECG analysis, visualization, and report generation

• Combination of single-lead wearable devices and AI algorithms creating a pathway towards cost-efficient Holter-style monitoring solutions

TORONTO, ON / ACCESS Newswire / January 20, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce a strategic collaboration with Movesense Ltd, a medical device manufacturer and wearable sensor technology provider based in Finland, designating Movesense as one of NeuralCloud’s primary ECG device partners.

The collaboration supports the development of bundled cardiac monitoring solutions that combine Movesense’s wearable single-lead ECG sensors with NeuralCloud’s AI-powered cardiac platforms, including MaxYield™, CardioYield™, and Insight360™. Together, these technologies enable high-quality ECG acquisition, automated signal enhancement, and scalable report generation across clinical, research, wellness, and performance environments.

Movesense’s programmable, lightweight wearable sensors-commonly deployed as chest-strap and body-worn single-lead medical ECG devices-offer a proven, flexible and cost-efficient hardware foundation. When paired with NeuralCloud’s AI-driven signal processing and visualization stack, the combined solution enables end-to-end ECG workflows that extend beyond traditional device-only or software-only approaches.

The collaboration also creates an opportunity to address segments traditionally served by higher-cost Holter monitoring systems. By pairing Movesense’s scalable wearable ECG sensors with AI-powered signal enhancement, labeling, and reporting, NeuralCloud aims to support solutions that can complement-and in select use cases potentially replace-conventional Holter workflows, while maintaining alignment with clinical standards and regulatory pathways.

Through Insight360™, users can generate customizable ECG reports using no-code, drag-and-drop dashboards designed for both everyday wellness users and professional clinical environments. CardioYield™ enables structured Holter-style review and reporting, while MaxYield™ serves as the underlying AI engine that denoises ECG signals, labels PQRST waveforms, and produces machine-readable interval data.

"This collaboration allows us to move beyond analytics in isolation and deliver a complete, integrated cardiac solution," said Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AIML. "By working with Movesense as a core device partner, we can combine high-quality single-lead ECG capture with advanced AI algorithms to support new monitoring models, including pathways toward Holter-style analysis and reporting using more accessible devices."

"This partnership strengthens our operational and commercial flexibility," said Erik Suokas, Chief Operating Officer of AI/ML Innovations. "Movesense provides a proven, scalable device platform that allows us to bundle hardware and AI software into unified offerings. This approach supports faster deployment, broader market reach, and more competitive solutions across wellness, monitoring, and clinical use cases."

"Movesense was built to enable flexible, high-quality ECG acquisition across a wide range of applications," said Jussi Kaasinen, CEO of Movesense. "Partnering with NeuralCloud allows our wearable devices to be paired with advanced AI-driven analysis and reporting. Together, we can support innovative cardiac monitoring solutions that are scalable, cost-effective, and designed to integrate seamlessly into modern digital health workflows."

"This collaboration reflects our broader strategy to embed AI-powered cardiac intelligence directly into real-world workflows," added Paul Duffy, Executive Chairman and CEO of AI/ML Innovations. "By combining wearable ECG hardware with our software platforms, we strengthen our go-to-market position and expand our ability to deliver complete, device-enabled cardiac solutions."

About Movesense

Movesense Ltd is a leading wearable sensor technology company specializing in ECG (electrocardiogram), heart rate, heart rate variability (HRV), and motion sensing for medical, sports, wellness, and research applications. Based in Finland, and being ISO13485:2016 Certified medical device manufacturer, Movesense develops and manufactures scalable, lightweight, durable, and programmable wearable sensors designed to integrate seamlessly into custom digital health solutions.

Movesense devices support single-lead ECG acquisition, commonly used in chest-strap and body-worn configurations, and are available in both medical and non-medical variants, enabling deployment across regulated healthcare, performance monitoring, and consumer wellness environments. With open APIs, developer tools, and flexible firmware, Movesense enables partners to rapidly build, brand, and scale connected cardiac monitoring solutions.

About AI/ML Innovations Inc.

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML’s shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

For detailed information please see AIML’s website or the Company’s filed documents at www.sedarplus.ca .

Contact:

Blake Fallis (778) 405-0882
blake@aiml.health

On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company’s products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

View the original press release on ACCESS Newswire

How AI Driven Discovery and Authority Recognition Reshaped Client Selection in Legal Services

POST FALLS, IDAHO / ACCESS Newswire / January 19, 2026 / Background and Initial Challenge

A mid sized law firm with a strong local reputation reached an unexpected growth plateau after years of steady expansion. Despite continued investment in website improvements, branding, and general online visibility, inbound leads stalled and new client inquiries became inconsistent.

Leadership began noticing a shift in how potential clients described their discovery process. More than 60 percent of new inquiries referenced AI tools as part of their initial research, often before visiting any law firm website. In several cases, the firm was not mentioned at all in AI generated answers, despite strong historical performance in traditional search.

This gap revealed a new competitive risk. Visibility alone was no longer determining consideration.

A Fundamental Shift in How Clients Choose Firms

Client discovery behavior had changed. Prospective clients were no longer comparing five or ten firms across search results. Instead, they were asking direct questions such as who handles this type of case or which law firm is trusted for this issue.

AI systems increasingly responded with a single firm recommendation. Internal analysis showed that when the firm was not surfaced by AI tools, it was excluded from consideration entirely before any human interaction occurred.

In practice, this meant competitive differentiation was happening earlier than ever, often before branding, messaging, or credentials were reviewed.

The Strategic Approach

Trustpoint Xposure reframed the challenge as an authority recognition issue rather than a marketing quality problem. AI systems do not evaluate persuasive language, visual design, or claims of expertise. They evaluate consistency, validation, and corroborated signals across trusted third party environments.

The strategy focused on aligning the firm with how AI systems assess credibility. Key initiatives included strengthening structured AEO signals, reinforcing reputation management across independent platforms, and securing targeted media placement to establish clear external validation.

The objective was to ensure AI systems could confidently identify the firm as a reliable and authoritative entity without relying on the firm’s own marketing materials.

Trustpoint Xposure is currently the only PR agency in the United States that has completed formal AEO certification and applies that certification through direct media access and AI answer validation.

Implementation and Early Results

Within four to six weeks of implementing the new structure, AI generated answers began to change. The firm started appearing consistently in response to relevant legal queries, often positioned as the primary recommendation rather than one of many options.

During intake calls, more than 45 percent of new clients referenced AI tools directly, frequently repeating language seen in AI summaries. Lead quality improved first, followed by increased volume.

Measurable Business Impact

Within three months, inbound leads increased by more than 110 percent. Average sales cycles shortened by approximately 30 percent because trust had already been established before the first conversation.

Revenue stabilized quickly and then returned to sustained growth, enabling leadership to move forward with initiatives that had previously been delayed. These included hiring additional staff, expanding practice areas, and increasing long term investment in authority driven visibility efforts designed to perform in AI mediated discovery environments.

Key Takeaways for Professional Services Firms

This case illustrates that success in AI driven discovery is not driven by short term tactics or incremental optimization. Firms asking how to rank first in AI search must focus on durable authority that is recognizable outside their own website.

Authority must be structured, validated, and reinforced across trusted third party environments that AI systems can independently verify. Firms that adapt early gain a compounding advantage. They are not simply found more often. They are selected before the first call ever takes place.

Media Contact
Jack Smith
Media Director
contact@trustpointxposure.com

SOURCE: Trustpoint Xposure

View the original press release on ACCESS Newswire

Starring Ashton James and Blair Underwood; In North American theaters on March 6, 2026

NEW YORK, NY / ACCESS Newswire / January 13, 2026 / Last week, Dolphin (NASDAQ:DLPN) released the official trailer and key art for YOUNGBLOOD, the upcoming sports drama from Academy Award® nominee Hubert Davis (The Well, Black Ice), giving audiences a first glimpse of the contemporary reimagining of the beloved 1986 hockey classic.

VIEW TRAILER HERE
DOWNLOAD POSTER & FILM STILLS HERE

The film follows hockey prodigy Dean Youngblood, who leaves Detroit to pursue his professional dreams with the Hamilton Mustangs in Canada. Raised on discipline and toughness by his father, Dean enters the league with undeniable talent – and an arrogance that quickly puts him at odds with teammates and rivals alike. As he confronts toxic behavior both on and off the ice, Dean must decide what kind of man and player he wants to become.

The cast includes Ashton James (Boxcutter, Revenge of the Black Best Friend) in the title role of Dean Youngblood, Blair Underwood (Longlegs, Deep Impact, LA Law) as his father Blane Youngblood, Shawn Doyle (The Expanse, Fargo, Big Love) as Coach Chadwick, Alexandra McDonald (Night Blooms, Testament) as Jessie Chadwick, Henri Picard (The Dishwasher, For Those Who Don’t Read Me) as Denis Sutton, Donald MacLean Jr. (Workin’ Moms, Nurses) as Carl Racki, Olunike Adeliyi (The Expanse, Workin’ Moms) as Ruby Youngblood, Emidio Lopes (Painkiller, The Changeling) as Kelly Youngblood and Tamara Podemski (Outer Range, Reservation Dogs) as Ms. McGill.

YOUNGBLOOD made its world premiere at the 2025 Toronto International Film Festival, where it received a rapturous response from audiences – particularly the festival’s passionate hockey community – and earned strong critical acclaim.

The trailer and key art for YOUNGBLOOD are now available. Produced by Aircraft Pictures in association with Dolphin Entertainment and Canadian distributor Photon Films and Media, the film will be released in theaters across North America on March 6, 2026, by Well Go USA Entertainment in the U.S. and Photon Films and Media in Canada.

Dean Youngblood was raised by his father, Blane, on a diet of toughness and hockey. When Dean is invited to join the Hamilton Mustangs, he travels to Canada from Detroit where his skill commands respect and his arrogance earns him fast enemies. Coach Chadwick, resentful of being saddled with such a toxic player, keeps Dean benched game after game. Dean’s frustration builds, culminating in a violent outburst involving rival goon Carl Racki that costs the Mustangs a significant win.

As Team Captain Sutton takes him under his wing, Dean begins to buck Blane’s teachings and his growing maturity spurs a relationship with Jessie – Coach Chadwick’s daughter – who gives Dean a run for his money on and off the ice. His newfound resolve draws the ire of Racki, who provokes Dean during a game by attacking and seriously injuring Sutton. As the final game of the playoffs approaches, so does his showdown with Racki and Dean’s choice as to what kind of man he wants to be.

ABOUT WELL GO USA ENTERTAINMENT

Well Go USA Entertainment (www.wellgousa.com) is an Oscar®-nominated theatrical and home entertainment distribution label that specializes in bringing the best in action, genre, and independent films from the U.S. and around the world to North America. Well Go titles can be seen across a variety of platforms, including in theaters, on-demand, via DVD and Blu-ray, and on television, as well as on mobile and connected devices through martial arts and action channel Hi-YAH! (www.hiyahtv.com). Well Go USA Entertainment’s corporate headquarters is in Allen, Texas, with an additional office in Taiwan.

ABOUT DOLPHIN

Dolphin (NASDAQ:DLPN) is where cultural creation meets marketing execution. Founded in 1996 by Bill O’Dowd, Dolphin operates as both a venture studio-developing and investing in breakthrough content, products, and experiences-and a marketing consortium, featuring leading agencies across every communications discipline.

At its core, the venture studio creates, produces, finances, markets, and promotes new businesses and cultural ideas – ranging from acclaimed film, television, and digital content to consumer goods, live events and partnerships that define entertainment and lifestyle. Surrounding this entrepreneurial engine, Dolphin’s marketing prowess brings together best-in-class firms including 42West, The Door, Shore Fire Media, Elle Communications, Special Projects, and The Digital Dept. Together, this collective delivers unmatched cross-marketing expertise and relationships across every vertical of pop culture – from film, television, music, influencers, sports, hospitality, and fashion to consumer brands and purpose-driven initiatives. Dolphin marketing has been the recipient of many accolades, including #1 Agency of the Year on the Observer PR Power List in 2025, The PR Net 100, and the PR News Elite 120.

ABOUT AIRCRAFT PICTURES

Based in Toronto, Aircraft Pictures was founded by Anthony Leo and Andrew Rosen to create high quality, scripted content for kids, families, and young adults. Recent projects include the Netflix Global Top 10 drama series Geek Girl, the CBC/BBC scripted K-pop drama Gangnam Project; the YTV/Nickelodeon scripted comedy series Popularity Papers, the Apple TV+ series Circuit Breakers, the Hulu Original series Holly Hobbie; and the Academy Award® and Golden Globe Award nominated animated feature film The Breadwinner. For more information, visit www.aircraftpictures.com.

ABOUT PHOTON FILMS AND MEDIA

Launched in 2010, Photon Films and Media (photonfilms.ca), formerly Pacific Northwest Pictures, is a leading Canadian entertainment company specializing in the development, financing, production and distribution of feature films for the domestic and international marketplace. With an emphasis on high quality films from leading filmmakers in diverse genres, Photon Films brings those films to consumers with innovative forms of marketing and distribution across all distribution platforms.

Media Contacts:

Scott Feinstein | Sylvia Desrochers
42West
youngblood@42west.com

IR Contact:

James Carbonara
HAYDEN IR
(646)-755-7412
james@haydenir.com

SOURCE: Dolphin Entertainment

View the original press release on ACCESS Newswire

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 13, 2026 / General Atomics Electromagnetic Systems (GA‑EMS) has successfully integrated a dual‑instrument payload onto a GA‑150 satellite for NASA Goddard Space Flight Center’s Total and Spectral Solar Irradiance Sensor‑2 (TSIS‑2) mission. This milestone extends the decades‑long continuous record of solar irradiance, a dataset critical to advancing scientific understanding of how solar variability influences the Earth system and its atmosphere.

GA-EMS advances TSIS-2 mission, integrating dual-instrument payload onto its GA-150 satellite set for sun-synchronous orbit to gather high-quality continuous data to monitor environmental changes and atmospheric variances from space.

GA‑EMS designed and manufactured the GA‑150 satellite at its Centennial, Colorado facility, where payload integration was completed. The work included performance checkouts and instrument alignment. Building on these milestones, the company has received an Authority to Operate (ATO) under NASA’s risk management framework, underscoring operational readiness. A full spacecraft test will be conducted to verify end‑to‑end communications and overall system performance going into 2026.

Unlike its predecessor, TSIS‑1, which operates aboard the International Space Station, TSIS‑2 will fly as a freestanding mission on a dedicated GA‑150 satellite. This independent platform will allow TSIS‑2 to collect uninterrupted measurements in sun‑synchronous orbit, ideal for satellite missions gathering high‑quality data to monitor weather, environmental changes, and atmospheric variances from space.

"Integrating the TSIS‑2 payload onto the GA‑150 is a significant milestone for our team and the mission," said Scott Forney, president of GA‑EMS. "The dedicated GA‑150 platform will help ensure NASA receives the high‑quality data this mission is designed to deliver."

The dual‑instrument payload, developed under a separate NASA Goddard contract awarded to the University of Colorado Boulder’s Laboratory for Atmospheric and Space Physics (LASP), includes the Total Irradiance Monitor (TIM) and Spectral Irradiance Monitor (SIM). These sensors contribute to continuous and vital long‑term data measurements necessary for quantifying the sun’s influence on Earth’s ozone layer, atmospheric circulation, clouds, and ecosystems throughout extensive solar energy cycles.

"Building on the outstanding success of the TSIS-1 mission, which has delivered the most accurate and stable measurements of the total and spectral solar irradiance since its 2017 launch, the TSIS-2 mission will allow our team at LASP to continue to improve this essential continuous solar data record," said Erik Richard, Ph.D., LASP principal investigator for TSIS-2. "Leveraging LASP’s long-standing leadership in solar irradiance measurements and instrument calibration, and in close partnership with NASA and General Atomics, we are proud to deliver the total and spectral solar irradiance monitors that will extend this irreplaceable time-series with unprecedented accuracy for the global scientific community."

About General Atomics Electromagnetic Systems

General Atomics Electromagnetic Systems (GA-EMS) develops innovative technologies to create breakthrough solutions supporting operational environments from undersea to space. From electromagnetic, power generation and energy storage systems and space systems and satellites, to hypersonic, missile defense, and laser weapon systems, GA-EMS offers an expanding portfolio of capabilities for defense, government, and national security customers. GA-EMS also provides commercial products and services targeting hazardous waste remediation, oil and gas, and nuclear energy industries. For further information, visit ga.com/ems.

Media Contact EMS-MediaRelations@ga.com

About the Laboratory for Atmospheric and Space Physics at the University of Colorado Boulder

The Laboratory for Atmospheric and Space Physics at the University of Colorado Boulder (LASP) is revolutionizing human understanding of the cosmos. LASP is deeply committed to inspiring and educating the next generation of space explorers. From the first exploratory rocket measurements of Earth’s upper atmosphere to trailblazing observations of every planet in the solar system, LASP continues to build on its remarkable history with a nearly $1 billion portfolio of new research and engineering programs.

Media Contact media@lasp.colorado.edu

# # #

SOURCE: General Atomics Electromagnetic Systems

View the original press release on ACCESS Newswire